Compare Adobe Systems Inc (ADBE) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Bristol-Myers Squibb Co — how do they compare? Adobe Systems Inc trades at $255.71 (market cap $104.82B), while Bristol-Myers Squibb Co trades at $63.74 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.
| ADBE | BMY | |
|---|---|---|
Market Cap | $104.82B | $129.94B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $65.89 |
52-Week Low | $193.41 | $42.60 |
Enterprise Value | $106.26B | $163.92B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe Inc. (ADBE) is trading at $255.80, down 6.29% in the last 24 hours amid broader tech sector volatility. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $5.96 beating expectations of $5.82. Revenue growth remains robust at $23.77B in 2025, with net income margin expanding to 29.99%. Technical indicators show a bullish moving average signal but neutral oscillators, with key support at $252.
Adobe presents a compelling value opportunity with a P/E of 15.09 below historical averages, though AI competition and CEO transition risks warrant caution. Analyst consensus remains positive with 49.2% buy ratings and $248.86 price target, suggesting potential upside from current levels despite recent selloff.
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
